Aug 8, 2022
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES
Aug 1, 2022
CORMEDIX INC. TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 11
Jun 8, 2022
CorMedix to Participate at the JMP Securities Life Sciences Conference
May 12, 2022
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES
May 3, 2022
CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12
Apr 7, 2022
CORMEDIX INC. ANNOUNCES SCIENTIFIC ADVISORY BOARD TO SUPPORT COMMERCIALIZATION and pipeline development
Apr 4, 2022
CORMEDIX INC. to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 29, 2022
CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Mar 28, 2022
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH
Mar 22, 2022
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
Mar 17, 2022
CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER
Feb 28, 2022
CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH
Jan 4, 2022
CORMEDIX TO PARTICIPATE IN UPCOMING JANUARY CONFERENCES
Nov 9, 2021
CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 2, 2021
CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9
Oct 20, 2021
CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING CONFERENCES SHOWING PATIENT OUTCOMES AND ECONOMIC BURDEN OF CRBSI
Oct 4, 2021
CORMEDIX INC. ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
Sep 7, 2021
CORMEDIX INC. ANNOUNCES REGULATORY UPDATE
Aug 12, 2021
CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
